High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala
Abstract INTRODUCTION: Geographical, epidemiological, and environmental differences associated with therapeutic response to Chagas etiological treatment have been previously discussed. This study describes high seroconversion rates 72 months after benznidazole treatment in patients under 16 years f...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Medicina Tropical (SBMT)
|
| Series: | Revista da Sociedade Brasileira de Medicina Tropical |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822016000600721&lng=en&tlng=en |
| _version_ | 1818534936535105536 |
|---|---|
| author | Lucia Brum-Soares Juan-Carlos Cubides Iris Burgos Carlota Monroy Leticia Castillo Selene González Pedro Albajar Viñas Pedro Pablo Palma Urrutia |
| author_facet | Lucia Brum-Soares Juan-Carlos Cubides Iris Burgos Carlota Monroy Leticia Castillo Selene González Pedro Albajar Viñas Pedro Pablo Palma Urrutia |
| author_sort | Lucia Brum-Soares |
| collection | DOAJ |
| description | Abstract INTRODUCTION: Geographical, epidemiological, and environmental differences associated with therapeutic response to Chagas etiological treatment have been previously discussed. This study describes high seroconversion rates 72 months after benznidazole treatment in patients under 16 years from a project implemented by Doctors without Borders in Guatemala. METHODS: An enzyme-linked immunosorbent assay was used to detect Trypanosoma cruzi IgG antibodies in capillary blood samples from patients 72 months after treatment. Fisher's exact test was used to establish association between characteristics, such as sex, age, and origin of patients, and final seroconversion. Kappa index determined concordance between laboratory tests. The level of significance was set to 5%. RESULTS: Ninety-eight patients, aged 6 months to 16 years, were available for follow-up. Sex and origin were not associated with seroconversion. Individuals older than 13 were more prone to maintain a positive result 72 months after treatment, although results were not highly significant. Laboratory tests presented elevated Kappa concordance (95% CI) = 0.8290 (0.4955-1), as well as high (97%) seroconversion rates. CONCLUSIONS: The high seroconversion rate found in this study emphasizes the importance of access to diagnosis, treatment, and follow-up of individuals affected by Chagas disease. Moreover, it contradicts the idea that it is not possible to achieve a cure with the currently available drugs. This study strongly supports expanding programs for patients infected with T. cruzi in endemic and non-endemic countries. |
| first_indexed | 2024-12-11T18:18:07Z |
| format | Article |
| id | doaj.art-72aab153fc7844d79ef2c1e997d98285 |
| institution | Directory Open Access Journal |
| issn | 1678-9849 |
| language | English |
| last_indexed | 2024-12-11T18:18:07Z |
| publisher | Sociedade Brasileira de Medicina Tropical (SBMT) |
| record_format | Article |
| series | Revista da Sociedade Brasileira de Medicina Tropical |
| spelling | doaj.art-72aab153fc7844d79ef2c1e997d982852022-12-22T00:55:22ZengSociedade Brasileira de Medicina Tropical (SBMT)Revista da Sociedade Brasileira de Medicina Tropical1678-984949672172710.1590/0037-8682-0415-2016S0037-86822016000600721High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in GuatemalaLucia Brum-SoaresJuan-Carlos CubidesIris BurgosCarlota MonroyLeticia CastilloSelene GonzálezPedro Albajar ViñasPedro Pablo Palma UrrutiaAbstract INTRODUCTION: Geographical, epidemiological, and environmental differences associated with therapeutic response to Chagas etiological treatment have been previously discussed. This study describes high seroconversion rates 72 months after benznidazole treatment in patients under 16 years from a project implemented by Doctors without Borders in Guatemala. METHODS: An enzyme-linked immunosorbent assay was used to detect Trypanosoma cruzi IgG antibodies in capillary blood samples from patients 72 months after treatment. Fisher's exact test was used to establish association between characteristics, such as sex, age, and origin of patients, and final seroconversion. Kappa index determined concordance between laboratory tests. The level of significance was set to 5%. RESULTS: Ninety-eight patients, aged 6 months to 16 years, were available for follow-up. Sex and origin were not associated with seroconversion. Individuals older than 13 were more prone to maintain a positive result 72 months after treatment, although results were not highly significant. Laboratory tests presented elevated Kappa concordance (95% CI) = 0.8290 (0.4955-1), as well as high (97%) seroconversion rates. CONCLUSIONS: The high seroconversion rate found in this study emphasizes the importance of access to diagnosis, treatment, and follow-up of individuals affected by Chagas disease. Moreover, it contradicts the idea that it is not possible to achieve a cure with the currently available drugs. This study strongly supports expanding programs for patients infected with T. cruzi in endemic and non-endemic countries.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822016000600721&lng=en&tlng=enBenznidazoleChagasChronic infectionGuatemalaSeroconversion |
| spellingShingle | Lucia Brum-Soares Juan-Carlos Cubides Iris Burgos Carlota Monroy Leticia Castillo Selene González Pedro Albajar Viñas Pedro Pablo Palma Urrutia High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala Revista da Sociedade Brasileira de Medicina Tropical Benznidazole Chagas Chronic infection Guatemala Seroconversion |
| title | High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala |
| title_full | High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala |
| title_fullStr | High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala |
| title_full_unstemmed | High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala |
| title_short | High seroconversion rates in Trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in Guatemala |
| title_sort | high seroconversion rates in trypanosoma cruzi chronic infection treated with benznidazole in people under 16 years in guatemala |
| topic | Benznidazole Chagas Chronic infection Guatemala Seroconversion |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822016000600721&lng=en&tlng=en |
| work_keys_str_mv | AT luciabrumsoares highseroconversionratesintrypanosomacruzichronicinfectiontreatedwithbenznidazoleinpeopleunder16yearsinguatemala AT juancarloscubides highseroconversionratesintrypanosomacruzichronicinfectiontreatedwithbenznidazoleinpeopleunder16yearsinguatemala AT irisburgos highseroconversionratesintrypanosomacruzichronicinfectiontreatedwithbenznidazoleinpeopleunder16yearsinguatemala AT carlotamonroy highseroconversionratesintrypanosomacruzichronicinfectiontreatedwithbenznidazoleinpeopleunder16yearsinguatemala AT leticiacastillo highseroconversionratesintrypanosomacruzichronicinfectiontreatedwithbenznidazoleinpeopleunder16yearsinguatemala AT selenegonzalez highseroconversionratesintrypanosomacruzichronicinfectiontreatedwithbenznidazoleinpeopleunder16yearsinguatemala AT pedroalbajarvinas highseroconversionratesintrypanosomacruzichronicinfectiontreatedwithbenznidazoleinpeopleunder16yearsinguatemala AT pedropablopalmaurrutia highseroconversionratesintrypanosomacruzichronicinfectiontreatedwithbenznidazoleinpeopleunder16yearsinguatemala |